Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Cadaver Donor Renal Transplantation: A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy
Brief Summary: To compare in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy vs. our conventional therapy in recipients of first cadaver (CAD) kidneys.


Options:
A: Arm Label: Single-dose Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Single-dose rabbit Anti-thymocyte Globulin induction | Arm Label: Divided-dose Thymoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Biological: Divided-dose rabbit Anti-thymocyte Globulin induction | Intervention Type: BIOLOGICAL; Name: Single-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Single-dose Thymoglobulin | Intervention Type: BIOLOGICAL; Name: Divided-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Divided-dose Thymoglobulin
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/Sirolimus | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/MMF | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Neoral/Sirolimus | Intervention Type: DRUG; Name: Tacrolimus/Sirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Tacrolimus/MMF; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Neoral/Sirolimus; Assigned to Arm(s): C
D: Arm Label: Alemtuzumab High-Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional High-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: rabbit anti-thymocyte globulin, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Alemtuzumab Low- Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional Low-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: basiliximab, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Intervention Type: DRUG; Name: basiliximab; Assigned to Arm(s): Conventional Low-Risk Patients | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin; Assigned to Arm(s): Conventional High-Risk Patients | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: alemtuzumab; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: steroids; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients

Answer: B